fbpx

Equity Research of
Nordic Growth Companies

Author: johan@emergers.se

QLUCORE: Structural growth story on track with a slight expansion of long-term scope

Research Articles, Research

After the strong growth in Q1’22/23, sales bounced back in Q2’22/23, right in line with our forecast. With the process to CE marking of...

Read More

KEBNI: New targets reflect high conviction in strong growth across the board in 2023-2027

Research Articles, Research

The announcement of KebNi’s revised strategy and financial targets for 2023-2027 reflect a firm conviction in steady long term growth...

Read More

SIMRIS ALG: Ready to execute on a three-pronged roadmap to capture the most high-value opportunities

Research Articles, Research

Following the successful acquisition of Cyano Biotech GmbH in Q3, Simris is now moving forward with a three-pronged approach to value...

Read More

DLABORATORY: Strong growth and positive EBITDA a welcome shift in pace

Research Articles, Research

With a steep increase in revenue, 35% recurring revenue growth, turn to positive EBITDA of SEK 2.2m and a forward-leaning statement from...

Read More

TRADING IDEA – Short DAX – Stage set for a pullback   

TRADING IDEA

Image credit: TradingView Trading idea – Short DAX – Stage set for a pullback    After the strength seen across the...

Read More

NANEXA: Charging to enter triple clinical trials in the coming year

Research Articles, Research

Besides starting its third proprietary development project in Q2 (NEX-22, a long-acting formulation of liraglutide for treatment of type 2...

Read More

KEBNI: Saab order the portal to next level for KebNi

Research Articles, Research

With the SEK 76m volume order for IMUs from Saab, KebNi now enters the next level of monetising its IMU technology. The order however only...

Read More

CAPSEK | Preferensaktie för fortsatt satsning på skalbar tech | Intervju med vd Henrik Jerner

Okategoriserade

NORTHERN CAPSEK VENTURES | Med en portfölj bestående av 14 skalbara techbolag verksamma inom sektorer med starka underliggande...

Read More

GRANGEX: Upwards revision of reserves accompanied by strong macro backdrop

Research Articles, Research

GRÄNGESBERG EXPLORATION The ongoing preparations for the DFS of Dannemora has now yielded its second upwards revision, a 16% increase in...

Read More

NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market

Research Articles, Research

Nanexa’s next proprietary development project, NEX-22, is a long-acting formulation of liraglutide for treatment of type 2 diabetes...

Read More

Be first to read new research on growth stocks